Investigational antibody drug conjugates for solid tumors

Expert Opinion on Investigational Drugs

Volumn 20, Issue 8, 2011, Pages 1131-1149

  Sapra, Puja ^a   Hooper, Andrea T ^a   O'Donnell, Christopher J ^a   Gerber, Hans Peter ^a  

^a PFIZER INC   (United States)

Author keywords

Antibody drug conjugates; Cancer stem cells; Chemotherapy; Pharmacology; Therapeutic index; Tumor biology

Indexed keywords

2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; AGS 16M8F MALEIMIDOCAPROYLMONOMETHYLAURISTATIN F ANTIBODY DRUG CONJUGATE; AGS 5ME VALYLCITRULLYLMONOMETHYLAURISTATIN E ANTIBODY DRUG CONJUGATE; ANTHRACYCLINE; ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; BAY 794620; BEVACIZUMAB; BIIB 015; BRENTUXIMAB VEDOTIN; CAPECITABINE; CARBOPLATIN; CD 70 MALEIMIDOCAPROYLMONOMETHYLAURISTATIN F ANTIBODY DRUG CONJUGATE; CD 70 MALEIMIDOCAPROYLVALYLCITRULLYLMONOMETHYLAURISTATIN F MINOR GROOVE BINDING AGENT ANTIBODY DRUG CONJUGATE; CRIPTO SPDB DM 4 ANTIBODY DRUG CONJUGATE; DOCETAXEL; DUOCARMYCIN DERIVATIVE; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB; IMGN 388; INOTUZUMAB OZOGAMICIN; INTEGRIN ALPHA SPDB DM 4 ANTIBODY DRUG CONJUGATE; LAPATINIB; LORVOTUZUMAB MERTANSINE; MC CARBONIC ANHYDRASE 9 VALYLCITRULLYLMONOMETHYLAURISTATIN E ANTIBODY DRUG CONJUGATE; MDX 1203; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN VALYLCITRULLYLMONOMETHYLAURISTATIN E ANTIBODY DRUG CONJUGATE; SGN 75; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB MERTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY AFFINITY; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; CYTOTOXICITY; DESQUAMATION; DIARRHEA; DRUG BINDING; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; ERYTHEMA; FATIGUE; HUMAN; HYPERESTHESIA; KIDNEY CARCINOMA; LARGE CELL CARCINOMA; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MENINGITIS; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE CANCER; NEUROENDOCRINE DISEASE; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PANCREAS CARCINOMA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; SARCOMA; SIDE EFFECT; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CARCINOMA; TUMOR REGRESSION; UNSPECIFIED SIDE EFFECT; UTERUS CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 79960356302     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.582866     Document Type: Review

References (74)

1. Presta LG. Selection, design, and engineering of therapeutic antibodies. J Allergy Clin Immunol 2005;116:731-6; quiz 737 (Pubitemid 41400532)
2. Wu A.M, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46 (Pubitemid 41486395)
3. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69
4. Kim KM, McDonagh CF, Westendorf L, et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol Cancer Ther 2008;7:2486-97
5. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803
6. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65 (Pubitemid 36988057)
7. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84 (Pubitemid 36791396)
8. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37
9. Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem Pharmacol 2010;79:1544-52
10. Oflazoglu E, Stone IJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008;14:6171-80
11. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408 (Pubitemid 44036683)
12. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
13. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
14. Krop I, LoRusso P, Miller KD, et al. A phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients withHER2+ metastatic breast cancer who were previously treated with an anthracyclin, a taxane, capecitabine, lapatinib, and trastuzumab. In San Antonio Breast Cancer Symposium; San Antonio; 2009
15. Erickson HK, Widdison WC, Mayo MF, et al. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 2010;21:84-92
16. Law CL, Gordon KA, Toki BE, et al. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 2006;66:2328-37
17. Pollack VA, Alvarez E, Tse KF, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol 2007;60:423-35 (Pubitemid 46944592)
18. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-82 (Pubitemid 43342531)
19. Hwu P, Sznol M, Pavlick H, et al. A phase I/II study of CRO11-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. J Clin Oncol 2009;27(15S):ASCO Meeting Abstract 9032
20. Burris H, Saleh M, Bendell J, et al. A phase I/II study of CRO11-vcMMAE (CDX-011), an antibody-drug conjugate, in patients with locally advanced or metastatic breast cancer. In 32nd Annual San Antonio Breast Cancer Symposium; San Antonio, TX; 2009
21. Kuroda K, Liu H, Kim S, et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009;69:1579-85
22. Ma D, Hopf CE, Malewicz AD, et al. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12:2591-6
23. Gruss HJ, Kadin M.E. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin Haematol 1996;9:417-46 (Pubitemid 26362738)
24. Hsu SM, Waldron J, Xie SS, Hsu PL. Hodgkin's disease and anaplastic large cell lymphoma revisited. 1. unique cytokine and cytokine receptor profile distinguished from that of non-hodgkin's lymphomas. J Biomed Sci 1995;2:302-13
25. Diegmann J, Junker K, Gerstmayer B, et al. Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 2005;41:1794-801 (Pubitemid 41132643)
26. Adam PJ, Terrett JA, Steers G, et al. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 2006;95:298-306 (Pubitemid 44187590)
27. Junker K, Hindermann W, von Eggeling F, et al. CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 2005;173:2150-3 (Pubitemid 40675271)
28. Hishima T., Fukayama M, Hayashi Y, et al. CD70 expression in thymic carcinoma. Am J Surg Pathol 2000;24:742-6 (Pubitemid 30253513)
29. Agathanggelou A, Niedobitek G, Chen R, et al. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995;147:1152-60
30. Held-Feindt J, Mentlein R. CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer 2002;98:352-6 (Pubitemid 34188677)
31. Hintzen RQ, Lens SM, Koopman G, et al. CD70 represents the human ligand for CD27. Int Immunol 1994;6:477-80 (Pubitemid 24087241)
32. Ansell SM, Thomposon J, Infante J, et al. Targeting CD70 in non-Hodgkin lymphoma and renal cell carcinoma: a phase 1 study of the antibody-drug conjugate SGN-75. In 35th ESMO Congress; 2010
33. Gudas JM, An Z, Morrison RK, et al. ASG-5ME: a novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers. In 2010 Annual Asco Meeting, Genitourinary Cancers Symposium; 2010
34. Gudas JM, Torgov M, An Z, et al. Use of AGS-16M8F as a novel antibody drug conjugate (ADC) for treating renal cancers. J Clin Oncol 2010;28:Suppl.518-27
35. Petrul H, Ranges G, Bouret E, et al. In vitro and in vivo efficacy of the anti-MN immunoconjugate BAY 79-4620, MN-IC, in MN (CAIX) expressing preclinical tumor models. In AACR Meeting; Washington, DC; 2010
36. Schatz C, Pena CE, Petrul H, et al. Efficacy and candidate biomarker evaluation for the anti-MN immunoconjugate BAY 79-4620, MN-IC in MN (CAIX) positive preclinical xenograft models. In AACR; Washington, DC; 2010
37. Bianco C, Rangel MC, Castro NP, et al. Role of Cripto-1 in stem cell maintenance and malignant progression. Am J Pathol 2010;177:532-40
38. Bianco C, Strizzi L, Normanno N, et al. Cripto-1: an oncofetal gene with many faces. Curr Top Dev Biol 2005;67:85-133 (Pubitemid 43631284)
39. Bianco C, Cotten C, Lonardo E, et al. Cripto-1 is required for hypoxia to induce cardiac differentiation of mouse embryonic stem cells. Am J Pathol 2009;175:2146-58
40. Campisi I, Granata OM, Cocciadiferro L, et al. 16alpha-hydroxyestrone inhibits estrogen sulfotransferase activity in human liver cancer cells. Ann NY Acad Sci 2009;1155:237-41
41. Cocciadiferro L, Micli V, Kang KS, et al. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. Ann NY Acad Sci 2009;1155:257-62
42. Watanabe K, Meyer MJ, Strizzi L, et al. Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 2010;28:1303-14
43. Glaser S, Van Vlijmen H., Lugovskoy A. A. & Sanicola-Nadel M. Cripto binding molecules. (ed. U.P. Application). 2010
44. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010;28:2698-704
45. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008;68:9280-90
46. Lewis Phillips GD, Fields CT, Crocker L, et al. Potent anti-tumor activity of trastuzumab-DM1 antibodydrug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. In AACR Annual Meeting; 2008
47. Beeram M, Burris HA, Modi S, et al. A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). In ASCO Annual Meeting; 2008
48. Holden SN, Beeram M, Krop IE, et al. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer. J Clin Oncol Suppl 2008;22:4711-17
49. Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-dm1 for the treatment of human epidermal growth factor receptor 2 (HER2) -positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2010;29:5865-72
50. Vogel CL, Burris HA, Limcatani S, et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER-2 antibody-drug conjugate (ADC), in patients (pts) with HER-2 metastatic breast cancer (MBC): final results. In ASCO Annual Meeting; 2009
51. LoRusso PM, Girish S, Burris HA, et al. Population pharmacokinetics of Trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate given every 3 weeks (q3W) or weekly (qw) to patients with HER2-positive metastatic breast cancer (MBC). Cancer Res 2009;69:abstract Nr 5099
52. Burris HA, Vukelja S, Krop IE, et al. Pharmacokinetics (PK), safety, and efficacy of trastuzumab (T)-DM1, a HER2 antibody-drug conjugate (ADC), in patients with HER2+ metastatic breast cancer (MBC): phase I and phase II trial results. EJC Suppl 2010;53:213-14
53. Vater CA, Manning C, Millar H, McCabe F. Anti-tumor efficacy of the integrin-targeted immunoconjugate IMGN388 in preclinical models. Eur J Cancer 2008;6(Suppl):abstract 529
54. Thompson DS, Patnaik JC, Bendell K, et al. A phase I dose-escalation study of IMGN388 in patients with solid tumors J Clin Oncol. 2010;28:abstract 3058
55. Tassone P, Gozzini A, Goldmacher V, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2-deacetyl-N2-(3-mercapto- 1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004;64:4629-36 (Pubitemid 38856937)
56. Woll P, Lorigan PJ, O'Brien M. Clinical experience of IMGN901 (BB-10901, huN901-DM1) in patients with Merkel cell carcinoma (MCC). In AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther; Boston; 2009
57. McCann J, Fossella FV, Viallalona-Calero MA. Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma. J Clin Oncol 2007;15:2765-72
58. Fosella F, Woll PJ, Lorigan PJ. Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma. J Thorac Oncol 2009;4:abstract PD4.3.5
59. Diegmann J, Junker K, Loncarevic IF, et al. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes. Neoplasia 2006;8:933-8 (Pubitemid 44706243)
60. Cardarelli P, King D, Terrett J, et al. Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate. In AACR Annual Meeting 2008; 2008
61. Terrett J, Gangwar S, Rao-Naik C, et al. Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-CD70 antibody-toxin conjugates, results in long term cures. In AACR Annual Meeting 2007; 2007
62. Lyon RP, Ryan MC, Kostner H, et al. Conjugation and assay methodologies to screen for antibodies with optimal properties for use as antibody-drug conjugate. In AACR; Washington, DC; 2010
63. Zhou BB, Zhang H, Damelin M, et al. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23
64. Junutula JR, Flagella KM, Graham RA, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 2010;16:4769-78
65. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
66. Henderson LA, Baynes JW, Thorpe SR. Identification of the sites of IgG catabolism in the rat. Arch Biochem Biophys 1982;215:1-11 (Pubitemid 13194163)
67. Moldoveanu Z, Epps JM, Thorpe SR, Mestecky J. The sites of catabolism of murine monomeric IgA. J Immunol 1988;141:208-13
68. Ferl GZ, Kenanova V, Wu AM, DiStefano JJ III. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 2006;5:1550-8 (Pubitemid 44070492)
69. Alley SC, Zhang X, Okeley NM, et al. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 2009;330:932-8
70. Rybak JN, Trachsel E, Scheuermann J, Neri D. Ligand-based vascular targeting of disease. ChemMedChem 2007;2:22-40
71. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 2007;104:4071-6 (Pubitemid 47181580)
72. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605
73. Stohrer M, Boucher Y, Stangassinger M, Jain RK. Oncotic pressure in solid tumors is elevated. Cancer Res 2000;60:4251-5 (Pubitemid 30636613)
74. Weinstein JN van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol 1992;14:457-63